inactiv
wkv
vaccin
attract
easili
prepar
least
conceptu
present
antigen
moieti
similar
immun
system
encount
invad
viru
particl
addit
vaccin
present
multipl
protein
surfac
immun
recognit
figur
antibodi
detect
patient
sera
least
eight
differ
protein
may
viral
particl
membran
addit
matrix
envelop
e
four
orf
confirm
encod
addit
structur
protein
data
indic
multipl
epitop
protein
may
target
protect
antibodi
mice
vaccin
inactiv
sarscov
gener
antibodi
number
protein
includ
nucleocapsid
n
main
difficulti
encount
product
inactiv
vaccin
biosafeti
level
growth
larg
amount
pathogen
difficulti
ensur
viru
success
inactiv
sarscov
largescal
product
uvinactiv
viru
success
describ
number
laboratori
pursu
develop
inactiv
whole
sarscov
viru
vaccin
demonstr
induc
sarscov
neutral
antibodi
howev
demonstr
efficaci
live
sarscov
challeng
rare
one
studi
wkv
vaccin
shown
protect
pulmonari
sarscov
replic
balbc
mice
although
character
immun
respons
report
consortium
sar
acceler
vaccin
initi
prepar
wkv
sarscov
strain
vaccin
compar
immunogen
efficaci
combin
attenu
ad
express
either
n
protein
abil
protect
live
sarscov
challeng
permiss
mous
model
result
show
wkv
vaccin
presenc
absenc
alum
adjuv
provid
protect
live
sarscov
challeng
induct
high
level
neutral
antibodi
reduct
sarscov
load
respiratori
tract
compar
mockvaccin
mice
covlik
particl
also
develop
coexpress
sarscov
protein
e
n
protein
mous
hepat
viru
thu
mimick
wkv
prepar
shown
induc
neutral
antibodi
protect
mice
sarscov
replic
lung
direct
experiment
comparison
made
wkv
vaccin
lack
signific
clinic
diseas
mani
mous
model
howev
lead
one
question
whether
efficaci
would
maintain
host
sar
virul
wkv
also
test
ferret
model
show
clinic
sign
signific
lung
patholog
formalininactiv
wholeviru
urbani
strain
sarscov
without
adjuv
induc
neutral
antibodi
led
earlier
clearanc
viru
challeng
provid
mild
protect
ferret
lung
tissu
analyz
day
postchalleng
show
signific
chang
mock
vaccin
anim
time
point
may
late
reveal
vaccinationinduc
differ
diseas
author
comment
vaccin
immunolog
robust
consortium
also
test
wkv
compar
advector
n
vaccin
ferret
found
vaccin
induc
neutral
antibodi
respons
reduc
viral
replic
shed
upper
respiratori
tract
progress
viru
lower
respiratori
tract
vaccin
also
diminish
hemorrhag
thymu
reduc
sever
extent
pneumonia
damag
lung
epithelia
howev
despit
high
neutral
antibodi
titer
protect
incomplet
vaccin
prepar
administr
rout
test
formaldehydeinactiv
sarscov
use
vaccin
rhesu
monkey
vaccin
shown
safe
immunogen
induc
neutral
antibodi
howev
evid
protect
lack
one
two
pbsvaccin
monkey
show
clinic
sign
challeng
mild
inactiv
sarscov
vaccin
administ
human
subject
found
safe
well
toler
abl
elicit
sarscovspecif
neutral
antibodi
howev
lack
natur
challeng
data
efficaci
wide
accept
endogen
antigen
product
via
recombin
attenu
bacteri
viral
deliveri
yield
superior
tlymphocyt
respons
found
sarscovspecif
tcell
respons
similar
wkv
ad
vector
snvaccin
mice
suggest
wkv
may
induc
tcell
respons
equal
vector
vaccin
thu
accumul
data
indic
wkv
vaccin
safe
induc
sarscov
neutral
antibodi
even
activ
lymphocyt
howev
compel
evid
protect
efficaci
scant
absent
advantag
ad
vaccin
includ
lack
pathogen
human
especi
replicationdefici
mutant
oral
nasal
administr
promot
mucos
immun
wellcharacter
genom
ad
disadvantag
ad
compar
viral
deliveri
system
includ
limit
clone
capac
fact
human
ad
restrict
host
rang
often
make
anim
test
difficult
larg
percentag
human
popul
preexist
immun
vector
due
natur
infect
last
difficulti
may
circumv
use
protocol
differ
vector
eg
dna
vaccin
use
prime
immun
respons
follow
boost
recombin
ad
first
demonstr
ad
vector
encod
sar
protein
immunogen
rhesu
macaqu
immun
intramuscularli
combin
three
adbas
vector
n
protein
gener
antibodi
respons
spike
fragment
sarscovneutr
antibodi
tcell
respons
n
protein
vaccin
mice
recombin
sar
n
abl
induc
sarscovspecif
secret
tcell
prolifer
neutral
antibodi
protect
sarscov
challeng
advector
vaccin
first
test
mice
develop
recombin
ad
construct
express
gene
either
sarscov
n
protein
immun
sarscovsuscept
mice
vector
combin
either
intranas
intramuscularli
vaccin
induc
high
level
neutral
antibodi
antisarscov
n
protein
secret
significantli
reduc
viral
titer
rna
lung
challeng
mice
interestingli
although
intramuscular
rout
effect
induc
neutral
sar
serum
antibodi
intranas
rout
administr
induc
iga
effect
block
sarscov
replic
nose
lung
tissu
nasal
secret
find
suggest
intranas
administr
recombin
ad
n
protein
may
induc
crucial
protect
mucos
immun
studi
compar
adenovector
n
vaccin
prepar
inactiv
sarscov
combin
adeno
n
vaccin
induc
significantli
lower
neutral
antibodi
similar
antin
cell
compar
inactiv
sarscov
vaccin
inactiv
vaccin
provid
superior
protect
measur
sarscov
lung
titer
rna
also
compar
vaccin
ferret
model
ferret
show
clinic
sign
includ
fever
lung
damag
wholekil
sarscov
vaccin
combin
ad
encod
n
protein
induc
neutral
antibodi
respons
reduc
viral
replic
respiratori
tract
decreas
tissu
damag
thymu
lung
adeno
n
vaccin
deliv
intranas
elicit
poor
serumneutr
antibodi
respons
provid
best
protect
lung
replic
lung
damag
indic
serumneutr
antibodi
suffici
measur
protect
efficaci
vaccin
addit
despit
high
neutral
antibodi
titer
vaccin
protect
incomplet
vaccin
prepar
one
homolog
boost
administr
rout
suggest
combin
vaccin
may
necessari
provid
adequ
protect
sar
suscept
anim
human
adenoviru
construct
express
sarscov
protein
also
evalu
ferret
model
use
heterolog
human
chimpanze
ad
order
avoid
interfer
immun
respons
first
ad
vaccin
boost
vaccin
regimen
reduc
viral
load
sever
pneumonia
ferret
also
shown
immunogen
rhesu
macaqu
poxviru
recombin
attract
vaccin
vector
owe
eas
product
stabil
capac
encod
larg
gene
cytoplasm
gene
express
abil
induc
longlast
cellular
humor
immun
respons
replicationdefici
poxviru
vector
modifi
vaccinia
ankara
mva
strain
encod
sarscov
protein
deliv
either
intranas
intramuscularli
induc
neutral
antibodi
reduc
viral
replic
respiratori
tract
challeng
mice
recombin
vaccin
also
employ
one
ferret
studi
appar
increas
liver
patholog
vaccin
group
sarscov
challeng
data
suggest
liver
patholog
evalu
sarscov
vaccin
studi
report
shown
liver
damag
link
vaccin
sever
viral
bacteri
vaccin
platform
technolog
employ
encod
protein
sarscov
vaccin
develop
monkey
vaccin
intranas
parainfluenza
encod
sarscov
protein
produc
neutral
antibodi
significantli
reduc
viral
titer
respiratori
tract
challeng
parainfluenza
viru
encod
protein
also
protect
sarscov
challeng
hamster
inclus
e
protein
enhanc
efficaci
recombin
adenoassoci
viru
encod
sarscov
protein
vaccin
induc
sarscov
neutral
antibodi
tcell
respons
decreas
viral
titer
lung
damag
mice
ad
studi
intranas
administr
led
iga
product
improv
protect
sarscov
challeng
newcastl
diseas
viru
aviantrop
viru
exhibit
limit
replic
primat
respiratori
tissu
also
use
sarscov
vaccin
monkey
vaccin
newcastl
diseas
viru
express
protein
less
viru
lung
tissu
sarscov
challeng
replicationdefect
vesicular
stomat
viru
recombin
express
sarscov
protein
induc
neutral
antibodi
tcell
respons
provid
protect
immun
mice
sarscov
sever
recombin
strategi
test
immunogen
yet
efficaci
exampl
liveattenu
recombin
measl
virus
express
sarscov
n
protein
induc
high
antibodi
titer
cognat
antigen
anti
antibodi
sarscov
neutral
n
protein
induc
specif
cellular
immun
respons
rabi
vector
use
express
protein
elicit
neutral
antibodi
mice
recombin
baculovirus
express
n
protein
induc
humor
cellular
immun
respons
vaccin
mice
attenu
salmonella
express
sarscov
n
protein
elicit
cytotox
tlymphocyt
activ
induc
cell
mice
interestingli
intranas
vaccin
also
show
advantag
bacteri
system
induc
highest
igg
iga
level
subunit
vaccin
compris
purifi
antigen
advantag
owe
safeti
simplic
howev
protect
efficaci
sometim
lack
particular
exogen
produc
protein
typic
present
mhc
class
ii
thu
often
gener
robust
cytotox
tcell
respons
cov
protein
favorit
target
cov
subunit
vaccin
develop
sinc
viral
protein
contain
determin
known
elicit
protect
immun
respons
consequ
sarscov
glycoprotein
shown
respons
receptor
bind
cellular
attract
target
develop
vaccin
therapeut
approach
strongli
support
find
human
monoclon
antibodi
bind
ntermin
protein
potent
neutral
sarscov
infect
inhibit
syncytia
format
block
receptor
bind
moreov
protein
shown
induc
serumneutr
antibodi
confer
protect
immun
sarscov
challeng
mice
african
green
monkey
sinc
sever
protein
also
express
surfac
virion
figur
elicit
antibodi
detect
sera
convalesc
sar
patient
protein
may
also
use
augment
protect
immun
exampl
antibodi
protein
also
shown
neutral
activ
addit
also
shown
sarscov
protein
gener
tcell
respons
studi
anim
cov
vaccin
also
shown
cov
n
protein
may
repres
anoth
antigen
candid
vaccin
develop
although
antibodi
cov
n
protein
virusneutr
activ
vitro
evid
protein
may
provid
vivo
protect
induct
cellmedi
immun
shown
gener
covspecif
cell
provid
protect
anim
follow
infect
express
sarscov
n
protein
shown
vaccin
candid
induc
antigenspecif
tcell
respons
vivo
protect
experi
perform
vaccin
review
publish
recent
address
progress
subunit
vaccin
mani
pathogen
antibodi
tcellmedi
immun
desir
outcom
vaccin
gener
liverecombin
attenu
organ
vaccin
effici
induc
cellular
immun
dna
vaccin
compris
plasmid
dna
encod
protein
pathogen
demonstr
induc
humor
cellular
immun
respons
latter
due
mimick
effect
live
virus
antigen
protein
endogen
produc
effici
present
mhc
class
thu
induc
tcell
respons
furthermor
stabil
simplic
safeti
eas
manufactur
make
dna
vaccin
attract
altern
use
live
vaccin
sever
dna
vaccin
candid
report
sarscov
protein
includ
n
protein
gener
antibodi
cellular
immun
respons
dna
vaccin
express
protein
induc
tcell
neutral
antibodi
respons
reduc
sarscov
replic
lung
furthermor
studi
show
protect
mediat
antibodi
gene
tcell
depend
mice
care
construct
plasmid
splice
site
viral
rna
export
sequenc
shown
markedli
increas
efficaci
sdna
vaccin
mous
model
vaccin
test
anim
model
multipleepitop
dna
vaccin
strategi
elicit
induct
antibodi
respons
mice
two
epitop
abl
neutral
sarscov
infect
vitro
protect
assess
mice
vaccin
ndna
vaccin
produc
nspecif
antibodi
cytotox
tlymphocyt
activ
although
one
studi
also
report
induc
delayedtyp
hypersensit
reaction
might
problemat
vaccin
ndna
vaccin
n
protein
express
link
lamp
order
enhanc
mhc
class
ii
present
increas
memori
respons
dna
vaccin
sarscov
n
protein
link
calreticulin
increas
mhc
class
present
gener
potent
nspecif
humor
tcellmedi
immun
respons
n
proteinexpress
cell
also
significantli
reduc
titer
challeng
vaccinia
viru
express
n
protein
data
suggest
respons
might
also
success
target
sarscovinfect
cell
ndna
vaccin
candid
also
investig
hlatransgen
mice
elicit
specif
tcell
respons
model
dna
vaccin
express
protein
also
shown
induc
neutral
antibodi
cytotox
tlymphocyt
activ
mice
interestingli
studi
compar
ndna
vaccin
gave
strongest
tcell
respons
although
dna
vaccin
show
great
promis
preclin
model
efficaci
clinic
studi
often
disappoint
thu
variou
strategi
develop
increas
efficaci
dna
vaccin
may
perform
conjunct
heterolog
prime
boost
protein
inactiv
viral
vaccin
candid
viral
vector
strategi
often
provid
superior
immun
respons
also
determin
magnitud
type
immun
respons
eg
dna
vaccin
sar
may
hold
promis
evid
protect
good
sar
anim
model
need
longlast
protect
vaccin
compris
attenu
pathogen
close
relat
avirul
live
viru
use
natur
occur
vaccinia
viru
lowvirul
member
genu
vaccin
smallpox
vaccin
efficaci
due
persist
host
possess
pathogenencod
immuneactiv
moieti
appropri
locat
bodi
cell
yield
endogen
protein
product
effici
mhc
class
present
gener
robust
cytotox
tcell
respons
difficulti
attenu
vaccin
attenu
point
mutat
may
revert
caus
virul
deletionattenu
mutant
may
recombin
natur
occur
environment
wild
virus
regain
virul
seen
attenu
oral
polioviru
given
safeti
concern
often
difficult
gain
regulatori
approv
attenu
vaccin
without
strong
proof
threat
diseas
suffici
warrant
use
vaccin
sar
threshold
yet
met
interest
attenu
mutant
develop
immunogen
protect
efficaci
liveattenu
vaccin
consist
recombin
sarscov
lack
small
e
gene
studi
delet
e
caus
reduc
viral
morphogenesi
viru
titer
vitro
vivo
thu
attenu
viru
hamster
immun
delet
mutant
develop
high
level
serumneutr
antibodi
protect
clinic
sign
decreas
activ
replic
homolog
sarscov
urbani
heterolog
sarscov
upper
lower
respiratori
tract
thu
delet
structur
e
gene
may
first
step
toward
develop
liveattenu
sarscov
vaccin
delet
gene
relat
cov
mous
hepat
viru
mhv
shown
creat
highli
efficaci
attenu
vaccin
suggest
approach
may
also
attempt
develop
sarsattenu
vaccin
two
comprehens
studi
gene
delet
attenu
effect
show
delet
orf
highlight
tabl
littl
effect
viral
replic
vitro
vivo
known
delet
gene
might
attenu
effect
higher
mammal
howev
given
disappoint
protect
afford
sarscov
vaccin
strategi
explor
date
seem
explor
attenu
sarscov
vaccin
justifi
vein
explor
undertaken
effect
rearrang
sarscov
genom
shown
attenu
mhv
system
addit
advantag
make
recombin
vaccin
wild
cov
thu
restor
virul
less
like
strategi
protect
virulencerestor
recombin
event
includ
multipl
attenu
gene
knockout
without
growth
viru
transcompl
cell
line
replac
transcript
regulatori
sequenc
analog
promot
system
sequenc
incompat
wildtyp
gene
express
strategi
fulli
elegantli
describ
recent
review
anim
model
develop
sar
includ
macaqu
african
green
monkey
ferret
mice
hamster
chines
mask
palm
civet
excel
review
anim
model
recent
releas
focu
newer
develop
especi
ferret
mous
model
question
use
efficaci
studi
reproduc
clinic
sign
sever
diseas
sar
human
unless
immunodefici
age
mice
use
howev
model
improv
use
mouseadapt
sar
human
transgen
mice
although
model
still
signific
caveat
hamster
also
exhibit
clinic
sign
sarscov
infect
ferret
use
wide
studi
influenza
suscept
sarscov
infect
lung
patholog
viru
shed
one
ferret
studi
indic
upon
intranas
administr
sarscov
toronto
strain
clinic
sign
observ
although
viral
rna
could
detect
pharyng
swab
howev
sever
studi
show
ferret
one
better
model
display
clinic
sign
viral
replic
lung
patholog
reflect
sar
pathogenesi
human
recent
report
ferret
studi
sarscov
challeng
result
ferret
clinic
sign
infect
elev
temperatur
nasal
discharg
sneez
anim
includ
cynomolgu
macaqu
report
regularli
experi
fever
common
sign
human
sarscov
infect
thu
ferret
good
model
sarscov
support
replic
upper
lower
respiratori
tract
develop
clinic
diseas
shed
viru
upper
airway
develop
sever
lung
patholog
ferret
also
outbr
allow
assess
rang
individu
respons
document
human
sar
final
ferret
model
nonrod
model
significantli
less
expens
difficult
studi
nonhuman
primat
main
disadvantag
model
ferret
immun
system
well
defin
dearth
reagent
outbr
larger
number
need
assess
statist
signific
greatest
fear
among
vaccinologist
creation
vaccin
ineffect
exacerb
diseas
unfortun
cov
vaccin
histori
enhanc
diseas
notabl
felin
cov
sever
mechan
may
exist
best
understood
antibodymedi
entri
viru
cell
via
immunoglobulin
fc
receptor
demonstr
occur
sarscov
protein
human
bcell
line
howev
group
show
sarscov
proteinvaccin
anim
show
sign
enhanc
lung
patholog
hepat
inde
viral
load
reduc
follow
challeng
sarscov
although
hamster
may
respond
way
similar
human
immunolog
group
also
shown
administr
anti
antibodi
enhanc
diseas
upon
sarscov
challeng
mice
ferret
suggest
antibodi
enhanc
diseas
sarscov
infect
two
report
possibl
vaccineinduc
patholog
sar
vaccin
trial
date
one
studi
ferret
vaccin
poxviru
vector
mva
express
sarscov
protein
display
increas
liver
patholog
challeng
compar
group
liver
patholog
increas
sarscov
vaccin
ferret
vaccin
trial
use
n
protein
note
delay
histopatholog
vaccin
group
increas
patholog
compar
unvaccin
group
lack
vaccin
enhanc
diseas
support
recent
studi
wkvvaccin
challeng
ferret
follow
week
howev
exact
detail
combin
vaccin
vector
antigen
may
control
phenomenon
studi
rais
vaccin
safeti
concern
vaccin
n
protein
express
venezuelan
equin
enceph
viru
replicon
particl
report
increas
eosinophil
infiltr
damag
lung
mice
challeng
sarscov
report
studi
studi
combin
n
protein
express
ad
eosinophil
infiltr
note
mice
ferret
vaccin
antigen
combin
must
thoroughli
evalu
safeti
efficaci
overal
pictur
sarscov
vaccin
show
particular
reason
concern
vaccin
enhanc
diseas
case
report
appear
confin
particular
express
system
rather
specif
relat
antigen
vast
major
studi
immunogen
elicit
without
neg
impact
health
challeng
virul
pathogen
individu
convalesc
sar
develop
high
titer
neutral
antibodi
appear
antibodi
coincid
onset
resolut
sar
pneumonia
addit
antibodi
sar
glycoprotein
whole
sarscov
administ
sever
anim
model
shown
prevent
reduc
sarscov
replic
diseas
howev
shown
inactiv
sar
alum
vaccin
induc
higher
serumneutr
antibodi
titer
vaccin
advector
vaccin
univers
protect
ferret
better
sarscov
challeng
data
provid
cautionari
note
sar
rodent
model
indic
induct
strong
neutral
antibodi
equat
protect
efficaci
relev
anim
model
clinic
sign
appar
signific
lung
damag
seen
abil
antibodi
neutral
viru
infect
easiest
activ
measur
import
function
antibodi
antivir
defens
import
lesson
may
drawn
field
poxvirolog
one
protect
antigen
gener
protect
antibodi
neutral
sever
report
indic
intranas
vaccin
may
provid
superior
protect
compar
rout
protollinformul
sar
protein
deliv
intranas
protect
mice
sarscov
replic
lung
better
vaccin
deliv
intramuscularli
despit
compar
serum
level
neutral
antisar
igg
presum
due
induct
iga
detect
intranas
vaccin
anim
found
similar
result
mice
ferret
vaccin
given
intranas
intramuscularli
gave
stronger
protect
deliv
intranas
rout
particularli
term
viral
load
lung
shed
nasal
secret
intranas
administr
increas
protect
despit
greatli
reduc
serum
antibodi
respons
data
underscor
import
mucos
immun
evalu
tlymphocyt
respons
sar
protect
problemat
rodent
may
provid
adequ
diseas
model
model
difficult
evalu
anim
outbread
inadequ
reagent
measur
tcell
respons
studi
need
determin
rel
contribut
humor
cellmedi
immun
protect
sar
diseas
interestingli
studi
compar
ndna
vaccin
gener
strongest
tcell
respons
recov
sar
patient
longlast
memori
antigen
data
suggest
research
direct
toward
evalu
potenti
efficaci
antigen
well
viral
protein
much
research
elucid
potenti
antigen
rout
vaccin
method
design
sar
vaccin
complet
immunogen
wide
demonstr
identif
correl
protect
gener
immun
respons
protect
clinic
sign
lung
damag
remain
elus
result
suggest
protect
sar
vaccin
possibl
howev
protect
mammal
suscept
sever
diseas
eg
ferret
human
may
difficult
mous
model
suggest
date
data
indic
efficaci
vaccin
strategi
might
heterolog
combin
intranas
system
vaccin
sinc
deliv
differ
aspect
protect
given
incomplet
protect
current
vaccin
seem
unwis
discount
tcell
respons
adequ
evalu
protect
might
afford
inclus
addit
viral
protein
especi
display
virion
surfac
infect
cell
sarscov
vaccin
develop
sinc
protect
diseas
demonstr
vaccin
test
anim
model
mimic
human
sar
diseas
vaccin
develop
improv
vaccin
efficaci
need
clear
antibodi
protein
offer
protect
sar
equal
appar
high
neutral
antibodi
titer
suffici
protect
anim
seriou
tissu
damag
sarscov
challeng
thu
like
necessari
gener
protect
tlymphocyt
respons
antibodi
sar
protein
improv
protect
data
collect
thu
far
suggest
strategi
includ
mucos
immun
coupl
heterolog
system
rout
vaccin
may
improv
efficaci
altern
develop
safe
attenu
sar
vaccin
may
abl
offer
qualiti
quantiti
immun
respons
requir
stop
seriou
sarscovinduc
tissu
damag
necessari
conduct
trial
direct
comparison
vaccin
combin
appropri
anim
model
close
mimic
human
diseas
cours
also
import
pursu
understand
role
tcell
immun
sar
sinc
littl
known
time
develop
improv
tcell
analysi
reagent
ferret
aid
endeavor
rate
sar
vaccin
progress
next
year
like
depend
perceiv
diseas
threat
sar
anoth
epidem
pandem
occur
fund
research
vaccin
develop
prioriti
likewis
efficaci
human
demonstr
anoth
sar
outbreak
among
popul
vaccin
control
subject
